The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621.
 
Mark J. Ratain
Stock and Other Ownership Interests - Biscayne Neurosciences
Consulting or Advisory Role - Aptevo Therapeutics; Ascentage Pharma; Cyclacel
Research Funding - Abbvie (Inst); Dicerna (Inst); Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - pending patent related to a genomic prescribing system; pending patent related to a genomic prescribing system (Inst); royalties related to UGT1A1 genotyping for irinotecan; royalties related to UGT1A1 genotyping for irinotecan (Inst)
Expert Testimony - multiple generic companies
Other Relationship - Value in Cancer Care Consortium
 
Toshihiko Doi
Consulting or Advisory Role - Amgen; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Sumitomo Group; Taiho Pharmaceutical
Research Funding - Abbvie; Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Daiichi Sankyo; Janssen; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; Novartis; Pfizer; Quintiles; Sumitomo Group; Taiho Pharmaceutical; Takeda
 
Maja J. De Jonge
No Relationships to Disclose
 
Patricia LoRusso
Consulting or Advisory Role - Alexion Pharmaceuticals; ARIAD; Chiltern; CytomX Therapeutics; Five Prime Therapeutics; Genentech; Genmab; Glenmark; Halozyme; Ignyta; Menarini; Novartis; Novella Clinical; Omniox; Roche/Genentech; Takeda
Research Funding - Alexion Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Genentech (Inst); Immunogen (Inst); Merrimack (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Tensha Therapeutics (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Genentech/Roche
 
Martin Dunbar
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Manoj Chiney
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Monica Motwani
No Relationships to Disclose
 
Jaimee Glasgow
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Adam Matthew Petrich
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Drew W. Rasco
Consulting or Advisory Role - Boehringer Ingelheim; Lilly
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Birdie (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Rexahn Pharmaceuticals (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Asana Biosciences
 
Emiliano Calvo
Stock and Other Ownership Interests - International Cancer Consultants; Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Abbvie; Amcure; AstraZeneca; Celgene; EUSA Pharma; Gerson Lehrman Group; Guidepoint Global; Janssen-Cilag; Nanobiotix; Novartis; Pfizer; PsiOxus Therapeutics; Roche/Genentech; Seagen; SERVIER
Speakers' Bureau - Novartis
Research Funding - AstraZeneca; BeiGene; Novartis; START
Travel, Accommodations, Expenses - Roche/Genentech
Other Relationship - Fundación INTHEOS